Immune checkpoint inhibitors (IOs) are established across multiple solid tumors. This session will focus on mechanisms of action, therapeutic targets, and data-driven considerations for treatment selection and integration into clinical practice.

Sponsored by: Pfizer Oncology Speaker: Sarah E. Sagorsky, MPAS, P.A-C

Tyrosine kinase inhibitors (TKIs) require ongoing monitoring and proactive toxicity management to maximize outcomes. This session focuses on the role of APPs in initiating, adjusting, and managing TKI therapy across solid tumors, including adverse effect profiles and clinical monitoring tools.

The lung and breast cancer treatment landscapes continue to evolve with novel targeted therapies, immunotherapies, and combination approaches. This session will explore how these emerging treatments are being integrated into clinical practice.

Antibody-drug conjugates (ADCs) are expanding rapidly across solid tumors. This session will equip APPs with essential tools to recognize and manage ADC-associated toxicities, reduce dose delays, and support patient quality of life during therapy.

Coordinated care delivery is essential to optimizing outcomes across the cancer continuum. This session will explore how APPs lead and contribute to structured treatment pathways—from diagnosis through survivorship—and how consistent care coordination enhances safety, efficiency, and patient experience. Emphasis will be placed on aligning APP workflows with institutional protocols, managing transitions between settings, and ensuring continuity of care through multidisciplinary collaboration.

Biomarker testing is the foundation of precision oncology. This session focuses on how APPs can advocate for timely testing, interpret results, and incorporate biomarker-driven therapies into treatment planning.

Sponsored by: AstraZeneca Speaker: Sara Beeler, ARNP

As immunotherapy evolves, diverse agents—including checkpoint inhibitors, BiTEs, and other emerging classes—present a wide spectrum of immune-related adverse events. This session will provide practical guidance to recognize, grade, and manage toxicities ranging from routine irAEs to acute complications such as cytokine release syndrome and neurologic events, with a focus on structured escalation and interdisciplinary collaboration.

Rapid therapeutic advancements in gastrointestinal, genitourinary, and gynecologic cancers demand up-to-date knowledge of how to incorporate targeted agents and novel combinations into practice. This session will focus on applying evidence-based strategies for sequencing treatment, managing resistance, and aligning care with the unique needs of each patient and tumor type.

Emotional distress is a frequent and often underrecognized component of the cancer experience, affecting patients, caregivers, and care teams at every stage—from diagnosis through survivorship or end-of-life care. APPs are uniquely positioned to identify psychosocial needs, initiate timely support, and foster compassionate communication. This session will explore the emotional impact of cancer, strategies to assess distress, and practical approaches for integrating emotional support into clinical workflows.